Results 51 to 60 of about 13,912 (195)

Eficacia terapéutica y eventos adversos de tratamientos para malaria vivax y malaria falciparum en gestantes en las regiones de Urabá y Alto San Jorge, Colombia, 2008-2011 Therapeutic efficacy and adverse events of treatments for vivax and falciparum malaria in pregnant women in the regions of Uraba and Alto San Jorge, Colombia, 2008-2011

Revista Colombiana de Obstetricia y Ginecología, 2013
Objetivo: evaluar, con el protocolo de la Organización Mundial de la Salud (OMS) de 1998, la respuesta terapéutica antimalárica (RTA) y los eventos adversos (EA) en cuatro esquemas de tratamiento antiplasmodial en gestantes colombianas, con diagnóstico ...
Jaime Carmona-Fonseca, Olga María Agudelo-García, Eliana Arango-Flórez   +2 more
doaj  

Knowledge among Drug Dispensers and Antimalarial Drug Prescribing Practices in Public Health Facilities in Dar es Salaam. [PDF]

, 2013
Irrational prescribing and dispensing of antimalarials has been identified as a contributing factor in the emergence of malaria parasites resistant to existing antimalarial drugs.
Kamuhabwa, Appolinary Ar, Silumbe, Richard   +1 more
core   +2 more sources

Response to Buffet et al: Intermittent preventive anti-malarial treatment to children (IPTc): firebreak or fire trap?

, 2008
Buffet and colleagues have reviewed some of the potential benefits and drawbacks of intermittent preventive antimalarial treatment in children (IPTc).
Bojang, Kalifa, Chandramohan, Daniel, Cisse, Badara, Greenwood, Brian, Kweku, Margaret, Milligan, Paul   +5 more
core   +1 more source

Some features of primary and recrudescent amodiaquine-resistant Plasmodium falciparum infections in Nigerian children

Memorias do Instituto Oswaldo Cruz, 2008
Characteristics of primary and recrudescent Plasmodium falciparum infections were evaluated in 25 children who did not recover after amodiaquine (AQ) treatment. Recrudescence was detected by a thick blood smear and confirmed by polymerase chain reaction.
Akintunde Sowunmi, Sulayman T Balogun, Grace O Gbotosho, Christian T Happi   +3 more
doaj   +1 more source

Unveiling Antimalarial Drug Resistance: The Role of CRISPR‐Cas Technologies in Malaria Research

Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 2026, Issue 1, 2026.
Background Malaria, caused by Plasmodium parasites, remains a global health burden, with drug resistance threatening control efforts. CRISPR‐Cas technologies, particularly CRISPR‐Cas9, have transformed malaria research by enabling precise genetic manipulations to study antimalarial resistance mechanisms, develop novel therapeutics and enhance ...
Reuben Samson Dangana, Israel Ehizuelen Ebhohimen, Moses Okpeku, Jess Vergis   +3 more
wiley   +1 more source

In vitro effects of amodiaquine on paired Schistosoma mansoni adult worms at concentrations of less than 5 µg/mL

Memorias do Instituto Oswaldo Cruz, 2013
In this study, the in vitro effects of amodiaquine (AQ) monotherapy on the egg output of paired adult Schistosoma mansoni worms and their survival during in vitro culture were assessed.
Kentaro Kato, Mitsumasa Miura, Yoshinori Mitsui   +2 more
doaj   +1 more source

Plasmodium falciparum genetic factors rather than host factors are likely to drive resistance to ACT in Ghana

Malaria Journal, 2020
Background Artemisinin-based combination therapy (ACT) partner drugs, currently used in Ghana are lumefantrine, amodiaquine and piperaquine. Plasmodium falciparum isolates with reduced susceptibility to these partner drugs may affect treatment outcome ...
Peter Hodoameda, Nancy Odurowah Duah-Quashie, Charles Oheneba Hagan, Sena Matrevi, Benjamin Abuaku, Kwadwo Koram, Neils Ben Quashie   +6 more
doaj   +1 more source

Amodiaquine for treating malaria

Cochrane Database of Systematic Reviews, 2003
Amodiaquine has been widely used to treat malaria. Fatal adverse reactions have been reported in adults taking it for prophylaxis. This has led some authorities to suggest it is withdrawn as a first line treatment for malaria.To compare amodiaquine with chloroquine or sulfadoxine-pyrimethamine for treating uncomplicated Plasmodium falciparum malaria.We
P, Olliaro, P, Mussano
openaire   +4 more sources

Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial. [PDF]

, 2018
BACKGROUND: Primaquine and methylene blue are gametocytocidal compounds that could prevent Plasmodium falciparum transmission to mosquitoes. We aimed to assess the efficacy and safety of primaquine and methylene blue in preventing human to mosquito ...
Bousema, Teun, Bradley, John, Brown, Joelle M, Chen, Ingrid, Diarra, Kalifa, Diawara, Halimatou, Dicko, Alassane, Drakeley, Chris, Gosling, Roly, Hwang, Jimee, Issiaka, Djibrilla, Keita, Sekouba, Kone, Daouda T, Lanke, Kjerstin, Mahamar, Almahamoudou, McCulloch, Charles, Müller, Olaf, Roh, Michelle E, Sanogo, Koualy, Soumare, Harouna M, Srinivasan, Vinay, Stone, Will JR, Traore, Sekou F   +22 more
core   +2 more sources

Ein neuer Malariawirkstoff hemmt die Proteinsynthese von Plasmodium falciparum

Angewandte Chemie, Volume 137, Issue 49, December 1, 2025.
Die Verbindung 31 stellt einen vielversprechenden Ansatz für die Entwicklung eines Malariawirkstoffs mit einem starken Wirkungsprofil dar (PfNF54 IC50 ± s.d. = 3,9 ± 0,4 nM). Sie hat einen neuartigen Wirkmechanismus, indem sie an zytosolische Ribosomen‐Untereinheiten bindet und dadurch die Proteinsynthese im Parasiten hemmt.
Patricia Bravo, Eleonora Diamanti, Mostafa M. Hamed, Lorenzo Bizzarri, Natalie Wiedemar, Armin Passecker, Nicolas M. B. Brancucci, Anna Albisetti, Christin Gumpp, Boris Illarionov, Markus Fischer, Matthias Witschel, Tobias Schehl, Hannes Hahne, Pascal Mäser, Matthias Rottmann, Anna K. H. Hirsch   +16 more
wiley   +1 more source